Marom Bikson PhD , Andre R. Brunoni MD PhD , Mark S. George MD
{"title":"US FDA approves home-delivered tDCS for treating depression","authors":"Marom Bikson PhD , Andre R. Brunoni MD PhD , Mark S. George MD","doi":"10.1016/j.brs.2025.103021","DOIUrl":null,"url":null,"abstract":"<div><div>On Dec 8, 2025, the US Food and Drug Administration (FDA) approved the Flow Neuroscience transcranial Direct Current Stimulation (tDCS) device for the treatment of “moderate to severe major depressive disorder (MDD) in the current episode, either as monotherapy or as an adjunctive treatment, in patients 18 years and older who are not considered treatment refractory to medication.” This represents the first FDA premarket approval (PMA) for a home-use non-invasive brain-stimulation device specifically indicated for depression treatment. This is a major regulatory milestone in non-pharmacological treatment of depression, and paves the way for additional uses and new technologies of home-based neuromodulation.</div></div>","PeriodicalId":9206,"journal":{"name":"Brain Stimulation","volume":"19 1","pages":"Article 103021"},"PeriodicalIF":9.7000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain Stimulation","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1935861X25004231","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/30 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
On Dec 8, 2025, the US Food and Drug Administration (FDA) approved the Flow Neuroscience transcranial Direct Current Stimulation (tDCS) device for the treatment of “moderate to severe major depressive disorder (MDD) in the current episode, either as monotherapy or as an adjunctive treatment, in patients 18 years and older who are not considered treatment refractory to medication.” This represents the first FDA premarket approval (PMA) for a home-use non-invasive brain-stimulation device specifically indicated for depression treatment. This is a major regulatory milestone in non-pharmacological treatment of depression, and paves the way for additional uses and new technologies of home-based neuromodulation.
期刊介绍:
Brain Stimulation publishes on the entire field of brain stimulation, including noninvasive and invasive techniques and technologies that alter brain function through the use of electrical, magnetic, radiowave, or focally targeted pharmacologic stimulation.
Brain Stimulation aims to be the premier journal for publication of original research in the field of neuromodulation. The journal includes: a) Original articles; b) Short Communications; c) Invited and original reviews; d) Technology and methodological perspectives (reviews of new devices, description of new methods, etc.); and e) Letters to the Editor. Special issues of the journal will be considered based on scientific merit.